Servier, founded in 1954, is the first French independent pharmaceutical group. We are present in 148 countries, over 5 continents, with more than 21 200 employees, including close to 3000 in Research and Development, preparing the drugs of the future.
In 2015, 24% of Servier’s turnover was invested in Research and Development. Servier is currently developing 23 drug candidates in oncology, cardiology, metabolic diseases, neuropsychiatry and rheumatology. 92% of Servier's medicines are prescribed outside France with a turnover of 3.9 billion euros in 2015